BioInvent International AB
STO:BINV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioInvent International AB
Revenue
BioInvent International AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioInvent International AB
STO:BINV
|
Revenue
kr226.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
30%
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr1.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr28.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
24%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr2B
|
CAGR 3-Years
106%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
What is BioInvent International AB's Revenue?
Revenue
226.5m
SEK
Based on the financial report for Dec 31, 2025, BioInvent International AB's Revenue amounts to 226.5m SEK.
What is BioInvent International AB's Revenue growth rate?
Revenue CAGR 10Y
30%
Over the last year, the Revenue growth was 407%. The average annual Revenue growth rates for BioInvent International AB have been -11% over the past three years , 9% over the past five years , and 30% over the past ten years .
